Thryv Therapeutics Inc. Announces the Presentation of Scientific Data for Its Novel SGK1 inhibitors at American Heart Association and San Antonio Breast Cancer Symposium

/PRNewswire/ - Thryv Therapeutics Inc., a biopharmaceutical company focused on a precision medicine approach to treat Long QT Syndrome (LQTS) via SGK1...

Related Keywords

Montreal ,Quebec ,Canada ,United States ,San Antonio ,Texas ,Chicago ,Illinois ,American ,Philip Sager ,Michael Ackerman ,Thryv Therapeutics Inc ,Therapeutics Inc ,Pharmacological Research In Cardiac Electrophysiology ,American Heart Association Scientific Sessions ,Glucocorticoid Regulated ,Congenital Long ,Genotype Specific Re Engineered Heart Cells ,Chief Medical Officer ,Action Potential Duration ,Re Engineered Heart Cell Models ,Therapeutic Approaches ,Mayo Clinic ,San Antonio Breast Cancer Symposium ,Molecular Biology ,Emerging Therapeutic ,Lqt Therapeutics Inc ,